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Introduction: Normal pregnancy is characterized by an elevated inflammatory state 
involving the placenta. The placental inflammation is further increased in preeclampsia, 
resulting in release of harmful danger signals to the maternal circulation. Activation of 
toll-like receptors (TLR)2 and TLR4 by endogenous danger signals plays a role in 
inflammatory diseases. Placental TLR2 and TLR4 expression has been reported, and 
high mobility group box 1 (HMGB1) is a likely endogenous activator of these receptors. 
We aimed to examine HMGB1 activation of TLR2 and TLR4 as mechanisms of 
placental inflammation in normal and preeclamptic pregnancies, by combined analysis 
of expression and function of the ligand HMGB1, the receptors TLR2 and TLR4, and 
the cytokine responder interleukin (IL)-8.  
 
Methods: Protein expression was analyzed in placental tissue from normal and 
preeclamptic pregnancies, and cytokine responses to two distinct HMGB1 isoforms 
were examined in placental explants and trophoblasts. Inflammatory and anti-
angiogenic markers were measured in maternal serum. 
 
Results: We demonstrated strong co-localized expression of HMGB1, TLR4 and IL-8 in 
the syncytium layer of the placenta. Syncytium TLR4 expression and maternal serum 
levels of IL-8 were significantly increased in preeclamptic compared to normal 
pregnancies. Functionality was confirmed by TLR4-dependent release of IL-8 from 
placental explants and trophoblasts in response to the inflammatory isoform of 
HMGB1. 
 
Discussion: This demonstrates a role for the HMGB1-TLR4 pathway at the syncytium 







Preeclampsia is described as an excessive maternal inflammatory response to a 
dysfunctional placenta or to pregnancy itself [1]. Impaired remodeling of the uterine 
arteries that supply blood to the placenta with subsequent insufficient blood flow may 
contribute to oxidative and inflammatory stress [1, 2]. The damaged placenta releases 
increasing amounts of inflammatory cytokines, anti-angiogenic factors and other danger 
signals to the maternal circulation, thereby aggravating maternal systemic endothelial 
dysfunction resulting in clinical manifestation of preeclampsia [2, 3]. The mature 
placenta is covered by the syncytium, a continuous layer of fused fetal cytotrophoblasts 
directly exposed to maternal blood [4]. Cytotrophoblasts underlie the syncytium  and 
are important for placental metabolism and maintenance of the syncytium [5]. The 
syncytium represents an important maternal-fetal interface that may be activated by 
inflammatory processes in the placenta and danger signals in maternal blood [6]. The 
harmful placental inflammation in preeclampsia is an exacerbation of normal pregnancy 
[1, 3]. Preeclampsia is often accompanied by fetal growth restriction (FGR) but whether 
these disorders share the underlying placental complications is uncertain [7]. 
Inflammation can be triggered by endogenous danger signals released to the 
extracellular environment by tissue damage such as trauma or ischemia/reperfusion 
injury [8]. High mobility group box 1 (HMGB1) is a nuclear transcription factor acting 
as a danger signal through Toll-like receptor (TLR)2 and TLR4 when released 
extracellularly [9, 10]. HMGB1 is a key inflammatory mediator in stroke and 
atherosclerosis [11] and its extracellular function depends on posttranslational redox 
modifications resulting in different isoforms [12]. The cytokine isoform of HMGB1 has 
a C23-C45 disulfide bond and initiates inflammation through TLR4 [13], resulting in 
release of inflammatory cytokines like interleukin (IL)-8 and tumor necrosis factor 
(TNF)-α [9, 14, 15]. The HMGB1 isoform with all cysteines reduced is a 
chemoattractant involved in tissue regeneration [13, 16, 17].  
The pathological processes necrosis [18], hypoxia [19] and oxidative stress [20] induce 
HMGB1 and are central to placental dysfunction in preeclampsia [1]. Maternal serum 
HMGB1 is elevated in preeclampsia [21-24] and the inflamed placenta is a likely source 
[25-28]. A role for HMGB1, TLR2 and TLR4 in placental inflammation in 
preeclampsia has been suggested by overall inconclusive separate expression studies in 
trophoblasts or placental tissue [24, 29-36]. The cell-specific distribution of these 
inflammatory pathways in the placenta therefore needs further characterization. We 
aimed to perform a comprehensive analysis of cellular distribution and functionality of 
HMGB1 activation of TLR2 and TLR4 to understand the contribution to placental 






This study was approved by the Norwegian Regional Committee for Medical and 
Health Research Ethics; the Preeclampsia Study (approval no. 2012/1040) and the First 
and Third Trimester Study (approval no. 2009/03). Informed written consent was 
obtained from all participants before enrollment. 
 
Study population 
The Preeclampsia Study includes healthy and preeclamptic singleton pregnancies with 
or without FGR recruited during 2002-2012 at St. Olavs and Haukeland University 
Hospitals, Norway. Maternal venous blood was collected prior to delivery and placental 
tissue after delivery by cesarean section without labor. To minimize differences in 
gestational age, additional maternal venous blood samples were collected from healthy 
pregnant women at gestational age 28–32 weeks recruited in 2013-2014. Non-pregnant 
women were enrolled at St. Olavs Hospital in 2013 for sampling of venous blood 
between days 6 and 11 of the menstrual cycle.  
Blood samples were left to clot for ≥ 30 min, centrifuged at 1800 x g for 10 min, and 
serum aliquots stored at -80°C. Third trimester placental biopsies were taken 
tangentially from the central part of the maternal side and directly fixed in 10% neutral-
buffered formalin before being paraffin embedded. 
Preeclampsia was defined as persistent hypertension (blood pressure ≥ 140/90 mmHg) 
plus proteinuria (≥ 0.3 g/24 h or reproducible ≥ 1 + by dipstick) developing after 20 
weeks of gestation [37]. FGR was either diagnosed by serial ultrasound measurements 
or established if the neonates had a birth weight < 5th percentile according to Norwegian 
reference curves [38]. Healthy normotensive pregnant women were included as normal 
pregnancy controls. 
The First and Third Trimester Study includes placental tissue from healthy singleton 
pregnancies recruited at St. Olavs Hospital during 2009-2014. First trimester placental 
tissue from surgical elective abortions (gestational age 7–12 weeks) were snap frozen 
and stored at -80°C until fixation and paraffin embedding. Third trimester placentas 
were collected from deliveries by cesarean section for immediate isolation of chorionic 
villous explants. Only the phenotypic parameters maternal and gestational age were 
obtained for these pregnancies. 
 
Clinical characteristics of study subjects 
Twenty-three preeclamptic and 13 healthy women were included in protein expression 
analyses of third trimester placentas, and among the preeclamptic pregnancies, 52% 
were additionally complicated by FGR and 70% experienced severe preeclampsia 
(Table 1). Thirty-four preeclamptic women, 43 healthy pregnant women and 28 healthy 
non-pregnant women were included in serum analyses, and among the preeclamptic 
pregnancies, 59% were additionally complicated by FGR and 79% had severe 
preeclampsia (Table 2). The gestational age ranges were 7–12 weeks for the ten first 
trimester placentas, and 38–39 weeks for the five healthy third trimester placentas 






Immunohistochemical staining and quantification 
Tissue sections (3 μm) were pre-treated in PT link (#PT101, Dako) using target retrieval 
solution (#K8005 or #K8004, Dako) at 97°C for 20 min and peroxidase blocking 
solution for 5 min (#K4007, Dako). Slides were stained for TLR2 (1:500, #AF2616, 
R&D Systems), TLR4 (1:175, #MAB14783, R&D Systems), IL-8 (1:200, #60141-2-ig, 
Proteintech), HMGB1 (1:80, #MAB1690, R&D Systems), CK7 (1:800, #M7018, 
Dako), CD31 (1:50, #M0823, Dako) or CD45 (1:300, #M0701, Dako). For detection of 
TLR2, 20 min incubation (1:400, #E0466, Dako) was followed by HRP-labeled 
streptavidin (#K1016, Dako) for 30 min. All other slides were incubated for 30 min 
with HRP-labeled polymer (#K4007, Dako). DAB+ (1:50, #K4007, Dako) was used as 
chromogen with two 5 min incubations and slides counterstained with hematoxylin. 
Mouse linker (#K8021, Dako) was used for TLR4 and cell marker staining.  
Immunohistochemistry was performed in Autostainer Plus (#S3800, Dako). Negative 
isotype controls were included (Fig. 1 C, F, I, L and Fig. S1 D, F, H). Bright field 
images were obtained with an Eclipse E400 microscope and DS-Fi1 camera (Nikon) or 
the EVOS™ FL Auto Imaging System (Invitrogen). The syncytium staining intensity 
was quantitatively assessed by automated image analysis using the NIS-Elements BR 
4.0 software (Nikon). The syncytiotrophoblast covering villous trees was delineated in a 
binary layer by manual adjustment. This binary layer defined the area included in 
automatic assessment of intensity values (the statistical mean of intensity pixel values). 
For HMGB1, positively stained syncytium nuclei were removed from analysis by a 
staining intensity threshold. The staining intensity score and protein expression level 
were inversely proportional. Three pictures per placental tissue section were taken of 
randomly selected areas with well-preserved placenta morphology, at 20x 
magnification. Protein expression was quantified in 13 healthy and 23 preeclamptic 
pregnancies, with the examiner blinded to pregnancy outcomes. 
 
Placental explants and trophoblasts 
A cotyledon was taken from the central region of fresh third trimester placentas and the 
fetal membrane and decidua basalis were removed. The chorionic villous tissue was 
washed in sterile phosphate-buffered saline supplemented penicillin-streptomycin and 
cut into pieces (explants) of similar weight (26.7 ± 8.0 mg). Explants were cultured in 
Ham’s F12/DMEM medium supplemented 10% FBS and 100 mg/ml penicillin-
streptomycin (Sigma-Aldrich) and incubated overnight at 37°C, 8% O2 and 5% CO2 
[39]. The trophoblast cell line SGHPL-5, generously provided by Prof. Whitley (St. 
George’s University of London, UK) [40] was chosen based on its functional TLR 
profile [41]. SGHPL-5 cells (passage 19-20) were seeded at 1 x 104 cells/well in Ham’s 
F10 medium supplemented 10% FBS, 2 mM L-glutamine and 100 mg/ml penicillin-
streptomycin and incubated overnight at 37°C, 20% O2 and 5% CO2. Fresh culture 
medium with or without the cytokine HMGB1 isoform (#HM-120) or the chemokine 
HMGB1 isoform (#HM-114) (IBL International) at 0.1–10 µg/ml (explants) or 1.25–20 
µg/ml (trophoblasts) were added and supernatants collected after 24 h (explants) or 4, 
24 and 72 h (trophoblasts), centrifuged and stored at -80°C. Viability was assessed by 
LDH cytotoxicity assay (#04744926001, Roche) (explants) or MTT analysis 
(trophoblasts), showing that the stimuli had no toxic effects (data not shown). 
Specificity was tested by adding 10 µM TLR4 inhibitor (#CLI-095, InvivoGen) [42, 43] 
one hour prior to HMGB1 stimulation. IL-1β, IL-6, IL-8, IL-9, IL-10, IL-12p70, 
interferon (IFN)-γ-inducible protein (IP)-10, TNF-α, IFN-γ and vascular endothelial 
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growth factor A (VEGF-A) in explant (1:50) and SGHPL-5 cell supernatants 
(undiluted) were analyzed by a customized multiplex cytokine assay (Bio-Rad 
Laboratories). For TLR4-inhibition experiments, IL-8 in supernatants from third 
trimester placental explants (1:1000) and SGHPL-5 cells (1:4) was measured in 
duplicate by sandwich ELISA (#DY208, R&D Systems). 
 
Serum measurements 
HMGB1 and soluble fms-like tyrosine kinase-1 (sFlt-1) were measured in duplicate 
serum samples by sandwich ELISA (#ST51011, IBL International and #DVR100B, 
R&D Systems, respectively). The intra- and inter-assay coefficient of variance for the 
HMGB1 ELISA was 0.3-6.5% and 20.8%, respectively. IL-8 was analyzed in maternal 
serum by cytokine assay (Human Cytokine Group I multiplex panel, # M50-0KCAF0Y, 
Bio-Rad Laboratories). The inflammatory marker C-reactive protein (CRP) (high 




Statistical analyses were performed in GraphPad Prism version 6.0 and SPSS version 21 
or 23 with P < 0.05 considered statistically significant. The specific tests used are 
described in corresponding table and figure legends and includes two-sided t-tests or 
Mann-Whitney U-test (comparing two groups), one-way ANOVA with Tukey's post-
hoc test or Kruskal-Wallis with Dunn's test (comparing three groups), or Chi-square test 
(categorical variables). Correlations was calculated using Pearson’s test or Spearman's 





Cell-specific placental expression of HMGB1 pathway components in preeclamptic and 
healthy pregnancies 
Cell-specific placental staining outlined the multinucleated syncytium layer (CK7), with 
underlying distinct cytotrophoblasts (CK7), fetal endothelial cells (CD31) and 
leukocytes (CD45) within the villous structures (Fig. S2). 
In third trimester placentas, strong expression of HMGB1 (Fig. 1A,B), TLR4 (Fig. 
1G,H) and IL-8 (Fig. 1J,K) was detected particularly in the syncytium and underlying 
cytotrophoblasts, and both nuclear and cytoplasmic HMGB1 expression was apparent. 
In addition, fetal endothelial cells and villous stromal cells expressed HMGB1, TLR4 
and IL-8 (Fig. 1A,B,G,H,J,K). TLR2 was expressed by leukocytes and endothelial cells, 
but not by the syncytium or cytotrophoblasts (Fig. 1D,E). The prominent third trimester 
syncytium HMGB1, TLR4 and IL-8 staining was quantified (Fig. 2). Cytoplasmic 
HMGB1 expression in the syncytium was higher in preeclamptic compared to normal 
pregnancies but did not reach statistical significance (preeclampsia 109 A.U. ± 7, 
preeclampsia+FGR 104 A.U. ± 8, healthy 110 A.U. ± 5, P = 0.079) (Fig. 2A). 
Syncytium TLR4 expression was significantly higher in preeclamptic compared to 
healthy placentas both in presence and absence of FGR (preeclampsia 94 A.U. ± 8, 
preeclampsia+FGR 98 A.U. ± 14, healthy 110 A.U. ± 13, P = 0.006) (Fig. 2B). The 
syncytium IL-8 expression levels did not differ between placentas from preeclamptic 
and healthy pregnancies (preeclampsia 146 A.U. ± 15, preeclampsia+FGR 136 A.U. ± 
13, healthy 146 A.U. ± 11, P = 0.097) (Fig. 2C). 
Expression of HMGB1, TLR2 and TLR4 was also investigated in first trimester 
placentas to assess variations throughout gestation (Fig. S1). TLR2 (Fig. S1G) and 
nuclear HMGB1 (Fig. S1C) were predominantly expressed in villous stromal cells and 
to a lesser extent in cytotrophoblasts, but not in the syncytium. TLR4 was strongly 
expressed in the first trimester syncytium and stromal cells (Fig. S1E).  
 
HMGB1 pathway functionality in placental explants and trophoblasts 
Functional response to the two HMGB1 isoforms was tested in third trimester placental 
explants (Fig. 3) and SGHPL-5 trophoblasts (Fig. 4). The cytokine HMGB1 isoform 
significantly increased the release of IL-6, IL-8, IFN-γ, TNF-α and VEGF-A from 
cultured chorionic villous explants after 24 h, while the chemokine HMGB1 isoform did 
not induce a cytokine response (Fig. 3A-E). Inhibition of TLR4-signaling confirmed a 
TLR4 dependent IL-8 response to the cytokine HMGB1 isoform (Fig. 3F). 
The cytokine HMGB1 isoform also activated cultured SGHPL-5 trophoblasts to release 
significantly higher levels of IL-8 after 4 h (5-fold increase) and 24 h (3-fold increase), 
whereas the chemokine HMGB1 isoform did not influence IL-8 production (Fig. 4A,B). 
Inhibition of TLR4-signaling in SGHPL-5 cells confirmed that the IL-8 response to the 
cytokine HMGB1 isoform was TLR4-dependent (Fig. 4C). Release of IL-6, IFN-γ, 
TNF-α and VEGF-A by SGHPL-5 trophoblasts was not affected by HMGB1 (not 
shown).  
 
Maternal serum levels of inflammatory and anti-angiogenic markers 
Serum levels of HMGB1 were measured in non-pregnant women (n = 28), healthy 
pregnant women (gestational age 28-40 weeks) (n = 43) and preeclamptic women at 
delivery (gestational age 25-39 weeks) (n = 34). Maternal serum HMGB1 was 
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significantly increased in preeclamptic (5.6 ng/ml [3.1 – 7.8]) and healthy pregnancies 
(4.5 ng/ml [1.4 – 7.4]) compared to non-pregnant women (1.9 ng/ml [0.7 – 3.5], P = 
0.0003) (Fig. 5A). 
Maternal serum levels of HMGB1 correlated positively with maternal serum levels of 
the mainly placenta-derived preeclampsia marker sFlt-1 [44] (Spearman’s r = 0.27, P = 
0.005) and the inflammatory marker CRP (Spearman’s r = 0.26, P = 0.008) (data not 
shown). The serum markers sFlt-1 and CRP were significantly increased in 
preeclampsia compared to normal pregnant and non-pregnant groups (Table 2). 
Maternal serum IL-8 were significantly increased in preeclamptic (34 pg/ml [29 – 45]) 





The pathway components HMGB1, TLR4 and IL-8 were here shown strongly co-
expressed at the syncytium, while TLR2 was not detected. The syncytium TLR4 
expression and maternal serum IL-8 were significantly increased in preeclampsia. 
Pathway functionality was confirmed by TLR4-dependent IL-8 release induced by the 
inflammatory isoform of HMGB1 in placental explants and trophoblasts. These data 
suggest involvement of isoform-specific HMGB1 activation of TLR4 in placental 
inflammation localized at the syncytium and a likely involvement in preeclampsia.  
HMGB1, TLR4 and IL-8, but not TLR2, were all expressed in the syncytium in third 
trimester placentas, advocating that the syncytium responds to HMGB1 through TLR4 
and not TLR2. The lack of syncytium TLR2 is supported by Ma et al. [34], while others 
have reported syncytium TLR2 staining [30, 32, 35]. This discrepancy could be 
explained by use of techniques to increase immunohistochemistry sensitivity or 
inadequate use of negative controls. The strong syncytium expression of TLR4 in early 
and late pregnancy is confirmed by others [30, 32, 34, 45], and highlights the 
importance of TLR4 at the maternal-fetal interface. Marked TLR4 expression on the 
syncytium side facing maternal blood [45] points to a protective function in normal 
pregnancy. In addition to TLR2 and TLR4, HMGB1 induces cytokine production 
through the receptor for advanced glycation end products (RAGE) [9]. Placental 
expression of RAGE has been shown to be increased in severe preeclampsia, but its 
expression and function needs to be further investigated to determine whether it 
functions as an additional placental receptor for HMGB1 [24, 32, 46]. Only nuclear 
HMGB1 was expressed in early pregnancy placentas, while the cytoplasmic HMGB1 
expression that precedes its extracellular release was found in third trimester placentas, 
pointing to HMGB1 as a more active mediator of placental inflammation at later 
gestation. To our knowledge, we are the first to assess the placental role of HMGB1 by 
cell-specific automated expression analysis of HMGB1 pathway components combined 
with functional HMGB1 isoform responses. 
The increased TLR4 expression in preeclampsia and functional response to HMGB1 
activation reported here substantiates a role in placental inflammation in preeclampsia, 
with the syncytium layer as the most important activation site. Since HMGB1 is 
abundantly expressed in placental cells and present in maternal serum, increased levels 
of its receptor TLR4 in the syncytium in preeclampsia is presumably sufficient for 
adverse activation. The increased syncytial TLR4 expression in preeclampsia is strongly 
supported [29, 30, 32, 47, 48] and may result from oxidative stress, a characteristic of 
the dysfunctional placenta in preeclampsia [1, 49]. TLR4 expression was increased in 
placentas from preeclamptic pregnancies despite their lower gestational age compared 
to controls, as it has been demonstrated that TLR4 activation and cytokine response 
increase with gestational age [50]. We did not adjust for the difference in gestational 
age and parity between groups since the difference is linked to the preeclampsia 
diagnosis and an adjustment may thus result in overadjustment bias, giving incorrect 
estimates of association [51]. The HMGB1 concentrations required to induce an in vitro 
TLR4 response were higher than the maternal serum HMGB1 levels. In vivo, the 
syncytium may be exposed to not only free serum HMGB1 but also to placental debris 
containing the danger signal, as well as HMGB1 released by the syncytium itself and by 
villous immune cells [21, 52]. Importantly, HMGB1 is not the only danger signal that 
can activate TLR4 in preeclampsia. Endogenous ligands for TLR4 are under intense 
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investigation and may involve molecules such as advanced glycation end products, 
oxidized lipoproteins and fibrinogen [10, 53]. Further examination is needed to reveal 
the complexity of danger signal involvement in preeclampsia.  
The syncytium layer plays a central role in maternal-fetal interaction by shedding 
immunologically active components and cellular debris to the maternal circulation [48]. 
Whether or not syncytium HMGB1 and IL-8 expression is increased in preeclampsia 
still remains uncertain due to inconsistent findings by us and others [24, 31-33, 36, 54], 
warranting investigation in larger and more defined disease subgroups. Syncytium 
HMGB1 and IL-8 can be released to the placental extracellular environment and the 
maternal circulation. Increased maternal serum HMGB1 in preeclampsia has been 
reported [22, 24], but the results are controversial since others have not observed such 
increase [33].  This discrepancy is probably not due to the gestational variation between 
cases and controls observed in this study, because it has been shown that serum levels 
of HMGB1 do not correlate with gestational age [22, 33]. This highlights the need for 
HMGB1 isoform profiling in placental tissue and maternal serum to understand the role 
of functionally different HMGB1 isoforms in preeclampsia [13]. The current lack of 
isoform-specific antibodies for HMGB1 useful for immune assays complicates such 
investigations. Liquid chromatography-tandem mass spectrometry (LC/MS) may be 
used for future studies [52]. IL-8 has been found elevated in maternal serum by us and 
others [55-57], and may contribute to the systemic endothelial dysfunction in 
preeclampsia [55, 56, 58-60].  
The inflammatory HMGB1-TLR4 pathway is shown at the syncytium as part of 
placental inflammation in normal third trimester pregnancies. By combined studies of 
pathway components, cellular players and functional responses, we have further 
indicated involvement of HMGB1-TLR4 in preeclampsia. In relation to the increase in 
HMGB1 [22-24] and IL-8 in maternal serum in preeclampsia, this points to a potentially 
harmful interdependent communication between the placental surface and maternal 
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Fig. 1. HMGB1, TLR2, TLR4 and IL-8 expression in third trimester placenta. Third 
trimester placentas from healthy (n = 13) and preeclamptic (n = 23; of which 11 were 
without and 12 with fetal growth restriction (FGR)) pregnancies were stained for (A, B) 
high mobility group box 1 (HMGB1), (D, E) Toll-like receptor (TLR)2, (G, H) TLR4 
and (J, K) interleukin (IL)-8. Representative images of (A, D, G, J) healthy placentas at 
gestational age 38+0 weeks and preeclamptic placentas at gestational age (B, H) 28+1, 
(E) 34+0 and (K) 29+0 weeks are shown. Third trimester placentas were stained with 
isotype controls matching the specific antibodies used for (C) HMGB1, (F) TLR2, (I) 






Fig. 2. Automated quantification of protein expression in third trimester placenta. For 
(A) high mobility group box 1 (HMGB1), (B) Toll-like receptor (TLR)4 and (C) 
interleukin (IL)-8, the syncytiotrophoblast staining was quantified by automated 
intensity analysis using NIS elements software, and data were analyzed using one-way 
ANOVA with Tukey's multiple comparison post-hoc test. *P < 0.05. **P < 0.01. A.U. 






Fig. 3. HMGB1 activated cytokine response in third trimester placental explants. Third 
trimester chorionic villous explants (n = 5) were incubated with either of the two 
isoforms of high mobility group box 1 (HMGB1) (0.1–10 µg/ml) for 24 h. Each of the 
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eight experimental conditions was performed with six replicates (n = 48 explants per 
placenta). (A-E) Cytokines were quantified in supernatants by multiplex analysis. (F) 
Toll-like receptor (TLR)4 inhibition was performed in third trimester placental explants 
(n = 2) by incubation with the cytokine HMGB1 isoform (0.1–10 µg/ml) with or 
without the TLR4-inhibitior CLI-095 (10 µM) for 24 h, and IL-8 in supernatants was 
quantified by ELISA. Data are presented as mean ± SEM of six replicates from each of 
five (A-E) or two (F) independent experiments with cytokine levels relative to explant 
weight. Data were analyzed using one-way ANOVA with Dunnett’s multiple 
comparison post-hoc test. ***P < 0.001, compared to the (A-E) unstimulated or (F) 
TLR4 inhibited condition. IFN indicates interferon; TNF, tumor necrosis factor; VEGF, 







Fig. 4. HMGB1 activated IL-8 response in SGHPL-5 trophoblasts. The trophoblast cell 
line SGHPL-5 was incubated with either of the two isoforms of high mobility group box 
1 (HMGB1) (1.25–20 µg/ml) for (A) 4 h or (B) 24 h. (A, B) Interleukin (IL)-8 was 
quantified in culture supernatant by multiplex analysis and is presented as mean ± SEM 
of triplicates from three independent experiments. (C) Toll-like receptor (TLR)4 
inhibition was performed in SGHPL-5 trophoblasts (n = 2) by incubation with the 
cytokine HMGB1 isoform (1.25–20 µg/ml) with or without the TLR4-inhibitior CLI-
095 (10 µM) for 24 h, and IL-8 in supernatants was quantified by ELISA. Data are 
presented as mean ± SEM analyzed using one-way ANOVA with Dunnett’s multiple 
comparison post-hoc test. *P < 0.05, ***P < 0.001, compared to the (A,B) unstimulated 







Fig. 5. Maternal serum levels of HMGB1 and IL-8. Serum levels of (A) high mobility 
group box 1 (HMGB1) and (B) interleukin (IL)-8 were measured in duplicate by ELISA 
in non-pregnant (n = 28), healthy pregnant (n = 43) and preeclamptic (n = 34) women. 
Data were analyzed using the Kruskal-Wallis test with Dunn’s multiple comparison 






Fig. S1. HMGB1, TLR2 and TLR4 expression in first trimester placenta. First trimester 
placentas (n = 10) were stained for expression of (A) hematoxylin erythrosine saffron 
(HES), (B) the trophoblast marker cytokeratin (CK)7, (C) high mobility group box 1 
(HMGB1), (E) Toll-like receptor (TLR)4 and (G) TLR2. Representative images of a 
placenta at gestational age (G) 11+5 or (A-C, E) 12+3 weeks are shown. CT and SCT 
indicate cytotrophoblasts and syncytiotrophoblast. First trimester placentas were stained 







Fig. S2. HES staining and cell type specific markers in third trimester placenta. Third 
trimester placentas from healthy and preeclamptic pregnancies were stained by (A) 
hematoxylin erythrosine saffron (HES), and immunohistochemical staining for (B) the 
trophoblast marker cytokeratin 7 (CK7), (C) the endothelium marker CD31 and (D) the 
leukocyte marker CD45. Representative images of a healthy placenta at gestational age 








Table 1. Clinical characteristics for subjects included in third trimester placental analyses 
(n = 36)  
  Preeclampsia Healthy pregnant 
 (n = 23) (n = 13) 
Baseline characteristics 
  
Maternal age (years) 30 (6)a) 32 (5)a) 
Primiparae (n, %) 12 (52)b),* 1 (8)b) 
Characteristics at delivery   
Body mass index (kg/m2) 29 (8)b) 29 (6)b) 
Systolic blood pressure (mmHg) 151 (12)a),* 119 (9)a) 
Diastolic blood pressure (mmHg) 100 (8)a),* 71 (9)a) 
Gestational age delivery (weeks) 32 (4)b),* 39 (1)b) 
Placental weight (g) 350 (193)b),* 580 (241)b) 
Fetal birth weight (g) 1780 (995)b),* 3590 (630)b) 
FGR, (n, %) 12 (52)b) n.a. 
Severe preeclampsiac), (n, %) 16 (70)b) n.a. 
Continuous variables are presented as a) mean with standard deviation or b) median with 
interquartile range. FGR, fetal growth restriction; n.a.; not applicable. Comparisons 
Comparisons between outcome groups (two-sided T-tests or Mann-Whitney U-test for  
continuous variables, Chi-square test for categorical variables): *P < 0.05 vs healthy 
pregnant. c) Preeclampsia was sub-phenotyped as severe if diagnosed with one or more 




Table 2. Clinical characteristics and markers for subjects included in serum analyses 
  
   
Preeclampsia                          
(n = 34) 
Healthy pregnant 
(n = 43) 
Non-pregnant 
(n = 28) 
Baseline characteristics 
Maternal age (years) 31 (6)a) 32 (4)a) 30 (5)a) 
Primiparae (n, %) 19 (56)b),* 4 (9)b) n.a. 
Characteristics at time of phlebotomy 
Body mass index (kg/m2) 28 (7)b),** 28 (6)b),** 22 (5)b) 
Systolic blood pressure (mmHg) 157 (22)a),*,** 115 (13)a) 111 (8)a) 
Diastolic blood pressure (mmHg) 99 (11)a),*,** 69 (9)a) 69 (7)a) 
GA at blood drawc) (weeks) 31 (4)b),* 38 (11)b) n.a. 
Characteristics at time of delivery 
GA delivery (weeks) 31 (4)b),* 39 (1)b) n.a. 
Placental weight (g) 280 (165)b),* 620 (190)b) n.a. 
Fetal birth weight (g) 1335 (876)b),* 3540 (335)b) n.a. 
FGR (n, %) 20 (59)b) n.a. n.a. 
Severe preeclampsiad) (n, %) 27 (79)b) n.a. n.a. 
Serum markers 
sFlt-1 (ng/ml) 1510 (1148)b),*,** 154 (227)b),** 0 (3)b) 
hsCRP (μg/ml) 4.5 (14.8)b),*,** 3.1 (3.3)b),** 0.5 (0.9)b) 
Continuous variables are presented as a) mean with standard deviation or b) median with 
interquartile range. FGR, fetal growth restriction; GA, gestational age; hsCRP, high 
sensitivity C-reactive protein; n.a., not applicable; sFlt, soluble fms-like tyrosine kinase. 
Comparisons between outcome groups (two-sided T-tests or Mann-Whitney U-test for 
comparisons of continuous variables between two groups, ANOVA and Tukey's test or 
Kruskal-Wallis and Dunn's test for comparisons of continuous variables between three groups 
Chi-square test for categorical variables): *P < 0.05 vs healthy pregnant.  
**P < 0.05 vs healthy non-pregnant. c) GA at blood draw differs from GA at delivery only for 
healthy pregnant controls sampled during pregnancy (n = 18). d) Preeclampsia was sub-
phenotyped as severe if diagnosed with one or more severe features [37, 61]. 
 
